title: Progress toward elimination of hepatitis B virus transmission in Oman: impact of hepatitis B vaccination.
abstract: Approximately 2-7% of the Omani population has chronic hepatitis B virus (HBV) infection. To decrease this burden, universal childhood hepatitis B vaccination was introduced in Oman in 1990. The hepatitis B vaccination strategy and reported coverage were reviewed. To assess the impact of the program on chronic HBV seroprevalence, a nationally representative seroprevalence study was conducted in Oman in 2005. Since 1991, hepatitis B vaccination in Oman has reached almost every eligible child, with reported coverage of ≥ 97% for the birth dose and ≥ 94% for three doses. Of 175 children born pre-vaccine introduction, 16 (9.1%) had evidence of HBV exposure, and 4 (2.3%) had evidence of chronic infection. Of 1,890 children born after vaccine introduction, 43 (2.3%) had evidence of HBV exposure, and 10 (0.5%) had evidence of chronic infection. Oman has a strong infant hepatitis B vaccination program, resulting in a dramatic decrease in chronic HBV seroprevalence.
authors: Office of H E of Health Affairs, Ministry of Health, Muscat, Sultanate of Oman; Department of Communicable Disease Surveillance and Control, Directorate General of Health Affairs, Ministry of Health, Muscat, Sultanate of Oman; Central Public Health Laboratory, Directorate General of Health Affairs, Ministry of Health, Muscat, Sultanate of Oman; Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
authors: Salah Thabit
authors: ST
authors: Al Awaidy
authors: Shyam Pandurang
authors: SP
authors: Bawikar
authors: Suleiman Salim
authors: SS
authors: Al Busaidy
authors: Salim
authors: S
authors: Al Mahrouqi
authors: Said
authors: S
authors: Al Baqlani
authors: Idris
authors: I
authors: Al Obaidani
authors: James
authors: J
authors: Alexander
authors: Minal K
authors: MK
authors: Patel
mesh_terms: D006509:Hepatitis B / Q000453:epidemiology / Q000517:prevention & control / Q000635:transmission* / Q000821:virology; D017325:Hepatitis B Vaccines / Q000008:administration & dosage / Q000276:immunology; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D007115:Immunization Schedule; D009850:Oman / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D013997:Time Factors; D014611:Vaccination
chemical_list: D017325:Hepatitis B Vaccines
references: Wkly Epidemiol Rec. 2004 Jul 9;79(28):255-63
references: 15344666
references: MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33; quiz CE1-4
references: 17159833
references: Bull World Health Organ. 2008 Mar;86(3):A-B
references: 18368190
references: Vaccine. 2010 Aug 23;28(37):5973-8
references: 20637773
references: Vaccine. 2012 Mar 9;30(12):2212-9
references: 22273662
references: MMWR Morb Mortal Wkly Rep. 2007 May 11;56(18):441-5
references: 17495790
references: J Infect. 2006 Mar;52(3):202-6
references: 16271396
references: Vaccine. 2007 Aug 10;25(32):5985-93
references: 17604881
references: Int J Epidemiol. 2005 Dec;34(6):1329-39
references: 16249217
references: Lancet Infect Dis. 2002 Jul;2(7):395-403
references: 12127351
references: J Infect Dis. 2009 Jul 1;200(1):39-47
references: 19469708